Rutgers University–New Brunswick is one of three regional campuses of Rutgers University, New Jersey's public research university. It is located in New Brunswick and Piscataway. It is the oldest campus of the university, the others being in Camden and Newark.

During the past decade, Rutgers conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 1 clinical trials were completed, i.e. on average, 25% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 1 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Rutgers" #1 sponsor was "Alexander Kusnecov, Ph.D." with 1 trials, followed by "American Gastroenterological Association" with 1 trials sponsored, "Gritstone bio, Inc." with 1 trials sponsored, "Incyte Biosciences International Sàrl" with 1 trials sponsored and "MedtronicNeuro" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Rutgers" #1 collaborator was "Loyola University Chicago" with 1 trials as a collaborator, "OpenBiome" with 1 trials as a collaborator, "RX.Health Inc." with 1 trials as a collaborator, "University of California, San Diego" with 1 trials as a collaborator and "University of Minnesota" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Rutgers" are "Acute Stroke" (1 trials), "Advanced Malignancies" (1 trials), "Clostridium Difficile Infection" (1 trials), "Colorectal Neoplasms" (1 trials) and "Epilepsy" (1 trials). Many other conditions were trialed in "Rutgers" in a lesser frequency.

Most popular intervention types in "Rutgers" are "Drug" (2 trials), "Device" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Ipilimumab" (2 trials), "Atezolizumab" (1 trials), "Bevacizumab" (1 trials), "Fluoropyrimidine plus leucovorin" (1 trials) and "GRT-C901" (1 trials). Other intervention names were less common.

The vast majority of trials in "Rutgers" are 5 trials for "All" genders.

Currently, there are NaN active trials in "Rutgers". undefined are not yet recruiting, 2 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Rutgers, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Rutgers, 1 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".